Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Marathon Digital Holdings Inc (MARA) vs Viatris Inc (VTRS) Price & Performance

Marathon Digital Holdings IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Marathon Digital Holdings Inc vs Viatris Inc — how do they compare? Marathon Digital Holdings Inc trades at $9.65 (market cap $3.83B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 5.2× Marathon Digital Holdings Inc's market cap, and Viatris Inc pays a 2.75% dividend while Marathon Digital Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marathon Digital Holdings Inc for 22 Days and Viatris Inc for 57 Days on average.

MARAVTRS
Market Cap
$3.83B$20.03B
Volume
47,742,69814,109,977
Sector
FinancialsHealth
52-Week High
$22.84$18.27
52-Week Low
$6.73$9.74
Typical Hold Time
22 Days57 Days
Enterprise Value
$5.87B$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Marathon Digital Holdings Inc

MARA trades at $9.91, down 4.34% today, with a bearish technical outlook despite some oversold RSI readings. The company faces severe profitability challenges with a net income margin of -429.71% and negative cash flow from operations of $802.73M in 2025. Recent earnings misses and declining revenue from $907M in 2025 to $804M in 2026 highlight operational struggles, though analyst consensus remains divided with a $13 price target.

The stock presents high risk due to persistent losses and negative cash generation, offset by potential upside if operational efficiency improves. Investors face volatility from Bitcoin sector exposure and regulatory uncertainty, requiring careful risk assessment despite Wall Street's mixed but leaning positive ratings.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MARA
78% Buy22% Sell
Avg holding period · 22 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About Marathon Digital Holdings Inc

Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.

Read more on MARA →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →